The Multidimensional Therapeutic Potential of Targeting the Brain Oxytocin System for the Treatment of Substance Use Disorders

2017 ◽  
pp. 269-287 ◽  
Author(s):  
Michael T. Bowen ◽  
Inga D. Neumann
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Therapeutic Potential ◽  
The Brain

Neuroplastic and cognitive impairment in substance use disorders: a therapeutic potential of cognitive stimulation

2019 ◽  
Vol 106 ◽  
pp. 23-48 ◽  
Author(s):  
Patricia Sampedro-Piquero ◽  
David Ladrón de Guevara-Miranda ◽  
Francisco J. Pavón ◽  
Antonia Serrano ◽  
Juan Suárez ◽  
...  
Keyword(s):  
Substance Use ◽  
Cognitive Impairment ◽  
Substance Use Disorders ◽  
Therapeutic Potential ◽  
Cognitive Stimulation

Brain Development and the Risk for Substance Abuse

2013 ◽  
pp. 706-715
Author(s):  
Kristina Caudle ◽  
B.J. Casey
Keyword(s):  
Substance Abuse ◽  
Substance Use ◽  
Brain Development ◽  
Substance Use Disorders ◽  
Animal Studies ◽  
Substance Abuse Problem ◽  
Increased Risk ◽  
Drug And Alcohol ◽  
The Brain ◽  
Developmental Window

Drug and alcohol dependence affects millions each year. Adolescence is a period of increased risk for substance use disorders. Understanding how the brain is changing during this developmental window relative to childhood and adulthood and how these changes vary across individuals is critical for predicting risk of later substance abuse and dependence. This chapter provides an overview of recent human imaging and animal studies of brain development focusing on changes in corticostriatal circuitry that has been implicated in addiction. Behavioral, clinical, and neurobiological evidence is provided to help elucidate who may be most at risk for developing a substance abuse problem and whenthey may be most vulnerable.

scholarly journals Adenosine A2AReceptors in Substance Use Disorders: A Focus on Cocaine

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1372 ◽  
Author(s):  
Karolina Wydra ◽  
Dawid Gawliński ◽  
Kinga Gawlińska ◽  
Małgorzata Frankowska ◽  
Dasiel O. Borroto-Escuela ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Current Knowledge ◽  
Ex Vivo ◽  
D2 Receptors ◽  
Future Research ◽  
Receptor Complexes ◽  
Abused Drugs ◽  
The Brain

Several psychoactive drugs can evoke substance use disorders (SUD) in humans and animals, and these include psychostimulants, opioids, cannabinoids (CB), nicotine, and alcohol. The etiology, mechanistic processes, and the therapeutic options to deal with SUD are not well understood. The common feature of all abused drugs is that they increase dopamine (DA) neurotransmission within the mesocorticolimbic circuitry of the brain followed by the activation of DA receptors. D2 receptors were proposed as important molecular targets for SUD. The findings showed that D2 receptors formed heteromeric complexes with other GPCRs, which forced the addiction research area in new directions. In this review, we updated the view on the brain D2 receptor complexes with adenosine (A)2A receptors (A2AR) and discussed the role of A2AR in different aspects of addiction phenotypes in laboratory animal procedures that permit the highly complex syndrome of human drug addiction. We presented the current knowledge on the neurochemical in vivo and ex vivo mechanisms related to cocaine use disorder (CUD) and discussed future research directions for A2AR heteromeric complexes in SUD.

scholarly journals Neuroscience-Informed Psychoeducation for Recovery (NIPER): A Program to Promote Metacognition in People with Substance Use Disorders

2020 ◽  
Author(s):  
Tara Rezapour ◽  
Mohammad Barzegari ◽  
Elham Sharifi ◽  
Nastaran Malmir ◽  
Hamid Reza Ghiasvand ◽  
...  
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Addiction Treatment ◽  
Randomized Clinical Trials ◽  
Recovery Process ◽  
Psychological Wellbeing ◽  
Treatment As Usual ◽  
Recovery Programs ◽  
Control Decision ◽  
The Brain

BackgroundA brief neuroscience-informed psychoeducation program (neuroscience-informed psychoeducation for recovery, NIPER) was developed to promote awareness (metacognition) in the main cognitive domains affected by drug and alcohol use to increase willingness to invest time and effort in the brain and cognition recovery process. The primary aim of this study was to determine the feasibility and acceptability of the NIPER program and its potential effectiveness in terms of increasing metacognition, psychological wellbeing and willingness for the brain and cognition recovery programs among people with substance use disorders (SUDs).Methodology56 individuals with SUDs recruited from four outpatient treatment centres in Tehran, Iran and attended four 90-min sessions delivered weekly adjunct to their treatment as usual. The effectiveness was measured in terms of metacognition, and psychological wellbeing at baseline and at the end of the program. Rate of adherence and participation as well as willingness to continue with brain and cognition recovery programs were measured as feasibility outcomes.ResultsA total of 51 participants completed the study. Compared to the baseline assessments, participants reported significantly higher problems in dimensions of attention, memory, inhibitory control, decision making, motor/speech, interocpetion and insight, as well as higher level of psychological wellbeing (t=4.66. p<0.001). In terms of feasibility outcomes, the adherence and participation rates were found above 85%. The majority of participants expressed their high willingness to continue the brain and cognition recovery programs (86.2%) and introduce NIPER to their peers (98%).ConclusionTaking into account the results in terms of feasibility and preliminary effectiveness of NIPER in clinical context of addiction treatment, we consider NIPER as a potentially beneficial interventions to be offered to people with SUD to increase their awareness and engage them to the brain and cognition recovery process. The clinical efficacy of the intervention should be tested in future randomized clinical trials.

Treatment of Comorbid Affective and Substance Use Disorders Therapeutic Potential of Anticonvulsants

1998 ◽  
Vol 7 (3) ◽  
pp. 210-220 ◽  
Author(s):  
Stephen J. Donovan ◽  
Edward V. Nunes
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
Therapeutic Potential

Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders

2000 ◽  
Vol 9 (10) ◽  
pp. 2233-2248 ◽  
Author(s):  
Adam Bisaga ◽  
Piotr Popik ◽  
Anton Y Bespalov ◽  
Wojciech Danysz
Keyword(s):  
Substance Use ◽  
Nmda Receptor ◽  
Substance Use Disorders ◽  
Therapeutic Potential ◽  
Nmda Receptor Antagonists ◽  
Receptor Antagonists

Immunology of Substance Use Disorders

2018 ◽  
pp. 165-178 ◽  
Author(s):  
Haitham Salem ◽  
Scott D. Lane ◽  
Antonio L. Teixeira
Keyword(s):  
Substance Use ◽  
Immune System ◽  
Substance Use Disorders ◽  
Stress Responses ◽  
Strategy Development ◽  
Drug Seeking ◽  
Reinforcing Effects ◽  
Immune Changes ◽  
The Brain

As in other psychiatric disorders, the role of the immune system is gathering increasing attention as an important mechanism in substance use disorders. Addiction is a complex condition in which a person engages in drug-seeking and drug-taking behaviors to accentuate the reward processes in the brain and avoid negative withdrawal states. Due in part to the activation of stress responses during drug withdrawal, high levels of peripheral pro-inflammatory cytokines are observed in this phase, and these immune changes might contribute to the behavioral negative reinforcing effects of the drug. This and other observations suggest that the immune system might play a role in the development of substance use disorders, also representing a potential target for biomarker and therapeutic strategy development (e.g., vaccines).

scholarly journals Mindfulness-based treatments for co-occurring depression and substance use disorders: what can we learn from the brain?

Addiction ◽  
2010 ◽  
Vol 105 (10) ◽  
pp. 1698-1706 ◽  
Author(s):  
Judson A. Brewer ◽  
Sarah Bowen ◽  
Joseph T. Smith ◽  
G. Alan Marlatt ◽  
Marc N. Potenza
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
The Brain

scholarly journals Substance use disorders: leading the road to recovery

2020 ◽  
Vol 11 (7) ◽  
pp. 741-744
Author(s):  
Emily K. Dennis ◽  
Sylvie Garneau-Tsodikova
Keyword(s):  
Substance Use ◽  
Substance Use Disorders ◽  
The Road ◽  
On The Road ◽  
The Brain ◽  
Opinion Article

Substance use disorders are diseases of the brain that create a dependency to various drugs. This opinion article provides an overview of the treatments available for these disorders and a perspective of what remains to be done on the road to recovery.

scholarly journals Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities

2021 ◽  
Vol 15 ◽  
Author(s):  
Mark D. Namba ◽  
Jonna M. Leyrer-Jackson ◽  
Erin K. Nagy ◽  
M. Foster Olive ◽  
Janet L. Neisewander
Keyword(s):  
Substance Abuse ◽  
Substance Use ◽  
Nervous System ◽  
Synaptic Plasticity ◽  
Substance Use Disorders ◽  
Immune Signaling ◽  
Treatment Targets ◽  
Novel Treatment ◽  
The Brain

Recent studies examining the neurobiology of substance abuse have revealed a significant role of neuroimmune signaling as a mechanism through which drugs of abuse induce aberrant changes in synaptic plasticity and contribute to substance abuse-related behaviors. Immune signaling within the brain and the periphery critically regulates homeostasis of the nervous system. Perturbations in immune signaling can induce neuroinflammation or immunosuppression, which dysregulate nervous system function including neural processes associated with substance use disorders (SUDs). In this review, we discuss the literature that demonstrates a role of neuroimmune signaling in regulating learning, memory, and synaptic plasticity, emphasizing specific cytokine signaling within the central nervous system. We then highlight recent preclinical studies, within the last 5 years when possible, that have identified immune mechanisms within the brain and the periphery associated with addiction-related behaviors. Findings thus far underscore the need for future investigations into the clinical potential of immunopharmacology as a novel approach toward treating SUDs. Considering the high prevalence rate of comorbidities among those with SUDs, we also discuss neuroimmune mechanisms of common comorbidities associated with SUDs and highlight potentially novel treatment targets for these comorbid conditions. We argue that immunopharmacology represents a novel frontier in the development of new pharmacotherapies that promote long-term abstinence from drug use and minimize the detrimental impact of SUD comorbidities on patient health and treatment outcomes.

Sign in / Sign up

Export Citation Format

Share Document